Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
A new type of intraperitoneal chemotherapy wash called NIPEC improves survival rates of mesothelioma surgical candidates by over 30% when combined with the current standard of HIPEC. The therapy involves several cycles of room-temperature chemotherapy and is in the early stages of research.
Written by Karen Selby, RN | Edited By Walter Pacheco | Last Update: August 29, 2024
Normothermic intraperitoneal chemotherapy, or NIPEC, is a room-temperature chemotherapy wash. Doctors administer it through an abdominal port. NIPEC, or NIPEC-LT, is a long-term treatment for malignant peritoneal mesothelioma patients.
It complements surgery by delivering consistent anti-cancer medication over multiple cycles. That complements surgery by delivering consistent anti-cancer medication over numerous cycles.
Delivering chemotherapy throughout the abdomen is called HIPEC, which is also known as hyperthermic intraperitoneal chemotherapy. HIPEC chemotherapy is administered warm and only once during cytoreductive surgery. NIPEC advances this method. It extends the anti-cancer effects of surgery and potentially improves disease-free survival.
Peritoneal specific questions I encounter commonly are what is the NIPEC procedure and how does a doctor determine whether that is done or not? Do they need further chemo after NIPEC?
For many years, chemotherapy has been systemic. It involves administering intravenous anti-cancer drugs through an IV line inserted in a vein or port. Systemic chemotherapy travels throughout the body in the bloodstream and eventually reaches cancerous cells through small blood vessels.
NIPEC is an innovative type of chemotherapy wash applied directly to cancerous tissue within the abdomen. Called a “chemo bath,” the chemotherapy medication fills and circulates in the abdominal cavity, killing cancer cells and reducing the chance of recurrence.
Evidence suggests NIPEC is most effective when combined with other chemotherapy washes.
HIPEC, EPIC and NIPEC are the three primary chemotherapy washes used to treat peritoneal mesothelioma. They vary based on temperature and length of treatment.
Patients have longer survival times when undergoing surgery with HIPEC, followed by EPIC and a series of NIPEC treatments. A 2022 study found that these interventions improved 5-year survival to about 80%.
The recommended administration of NIPEC is to give the first dose at four to six weeks postoperatively, followed by five more cycles with three weeks between each treatment.
This new treatment may offer advantages over other chemotherapy washes alone because it is a long-term therapy that eradicates cancer cells long after surgery.
Doctors are still developing the best techniques for administering NIPEC. It has shown promising results in gastric cancer, ovarian cancer and peritoneal mesothelioma.
Ovarian cancer and peritoneal mesothelioma are two cancers caused by asbestos-contaminated talc.
Dr. Paul H. Sugarbaker is a pioneer in peritoneal therapy. He has worked on NIPEC as a new standard that improves patient survival over HIPEC mesothelioma treatment and other washes.
The NIPEC procedure can be either an inpatient or outpatient procedure. Doctors deliver it once patients have recovered from surgery.
NIPEC administration involves several steps and multiple chemotherapy cycles. In most cases, surgeons install the port during the initial surgery.
After port removal, home care may involve regularly cleaning the wound, checking for infection and monitoring for any worsening signs or symptoms. Patients who undergo NIPEC should inform their doctor immediately if they notice worsening or persisting inflammation, discharge or fever.
Doctors administer NIPEC after surgery as an adjuvant treatment in a multimodal plan. Multimodal treatment offers many anti-cancer therapy methods working together to eradicate tumors.
Combining treatment improves survival times and the prognosis for mesothelioma.
NIPEC is still in its early stages. It is most effective after cytoreductive surgery when combined with other chemotherapy washes, such as HIPEC and EPIC.
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
We measure mesothelioma treatment success by the percentage of patients who live beyond five years, which doctors call the five-year survival rate.
NIPEC following HIPEC and post-surgical EPIC | 75% |
HIPEC followed by EPIC after surgery | 52% |
HIPEC alone administered during surgery | 44% |
NIPEC can improve peritoneal mesothelioma patients’ five-year survival rate. It increases surgical effectiveness alongside other chemotherapy washes, such as HIPEC.
Over twenty years ago, Sugarbaker helped create the current peritoneal mesothelioma treatment standard of HIPEC. Since then, he’s identified the technique’s shortcomings and developed NIPEC as the solution.
Surgeons first used NIPEC for ovarian cancer, but Sugarbaker explored its potential for peritoneal mesothelioma cancer in 2012.
In our study, the five-year survival rate went from 50% for those in the control group to more than 75% for those receiving the NIPEC. If others can duplicate the success that we’ve had, everyone will benefit. It will change the way people look at this disease, and the way it is treated.
Although the current results are impressive, Sugarbaker remains one of the few surgeons using it consistently today. He published a retrospective in 2020 of six malignant peritoneal mesothelioma patients treated with NIPEC. Four patients were free of disease after 8, 13, 18 and 19 years, and two patients died of illness 15 years after definitive treatment.
Due to its limited development, NIPEC is unavailable as a standard treatment at most mesothelioma treatment centers.
Sugarbaker currently serves as chief of the Peritoneal Surface Malignancy Program at the MedStar Washington Hospital Center in Washington, D.C., where patients may undergo NIPEC if they are eligible.
At MedStar Washington Hospital Center, Sugarbaker conducted his study on six peritoneal mesothelioma patients who lived eight to 19 years after receiving NIPEC.
As development on NIPEC continues, treatment centers are expanding the availability of HIPEC and other intraperitoneal treatments. Patients should consult with their mesothelioma specialist about the possibility of a chemotherapy wash as part of their treatment plan.
NIPEC is a long-term chemotherapy regimen with potential side effects. Side effects of chemotherapy wash such as NIPEC and HIPEC are usually fewer or milder than with systemic chemotherapy.
As with any procedure, NIPEC can cause complications. Complication risks will vary based on the patient’s overall health and stage of the disease.
While NIPEC offers many benefits to long-term survivability, it can also have some disadvantages. Patients should discuss the pros and cons with their doctor, as other treatment options may provide better benefits.
NIPEC is an exciting new treatment that may represent the future of peritoneal mesothelioma therapy. Combining long-term NIPEC with other chemotherapy washes has improved survival rates, but more research is still needed.
Researchers and specialists will continue to evaluate NIPEC for safety and effectiveness until the procedure becomes widely available.
This Page Contains 10 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family.LashawnMesothelioma patient’s daughter
Selby, K. (2024, August 29). NIPEC Treatment for Peritoneal Mesothelioma. Asbestos.com. Retrieved November 21, 2024, from https://www.asbestos.com/treatment/chemotherapy/nipec/
Selby, Karen. "NIPEC Treatment for Peritoneal Mesothelioma." Asbestos.com, 29 Aug 2024, https://www.asbestos.com/treatment/chemotherapy/nipec/.
Selby, Karen. "NIPEC Treatment for Peritoneal Mesothelioma." Asbestos.com. Last modified August 29, 2024. https://www.asbestos.com/treatment/chemotherapy/nipec/.
Mesothelioma Center - Vital Services for Cancer Patients & Families doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.